In cultured breast cancer cells (MCF7) treated with vinblastine, a microtubule-disrupting drug, the protective effect of NAD+ on microtubule loss requires sirtuin 3 (SIRT3), a mitochondrial NAD+-dependent deacetylase. Here, SIRT3 is linked to breast carcinoma.